Connect with our team at our booth or attend our session to discover how Clarivate's trusted data, expert consulting, and pharmacists-validated insights help life sciences team overcome today's toughest access and pricing challenges.
Join Clarivate in this timely discussion presented by a four-time Asembia speaker, Dee Chaudhary, recognized as an authority and advisor in access, pricing, and policy strategy.
The Inflation Reduction Act (IRA) has fundamentally reshaped the Medicare Part D landscape for specialty therapies — and new policy developments like renewed Most Favored Nation (MFN) pricing proposals and the recently passed One Big, Beautiful Bill (OBBB) are adding even more complexity.
Join us for an expert-led session where we break down what’s happening now — and what it means for manufacturers, access teams, and commercial strategy leaders.
Key takeaways:
Please note: This session is part of the Asembia 2026 Annual Meeting taking place at the Wynn & Encore Las Vegas in Las Vegas, NV. You must be registered for the main event to attend these sessions.
Register here for Asembia 2026.
Find out how we empower market access teams from strategy through execution to make smarter, faster decisions that bring treatments to patients sooner.
Exclusive first look: Introducing DRG Fusion, built to help market access teams understand where access expectations break down—and what’s actually driving performance in the field.
Cut through complexity with AI‑powered, pharmacist‑validated market access intelligence — bringing clarity to formulary coverage, medical policy, restrictions, and brand strategy optimization.
Arming commercial teams with anticipatory intelligence to maximize launch success and accelerate therapies to patients.